Hidradenitis suppurativa (HS)
HUMIRA is the first and only originator biologic* indicated in the treatment of HS†
HUMIRA is indicated for the treatment of active moderate to severe HS in adult and adolescent patients (12 to 17 years of age weighing ≥30 kg), who have not responded to conventional therapy (including systemic antibiotics).
* Also known as a reference biologic.
† Comparative clinical significance has not been established.
HS patient profiles
AN count=total abscess and inflammatory nodule count.
* HS-related skin pain was based on the worst pain in the previous 24 hours using a numeric rating scale (NRS), with 0 indicating no pain and 10 indicating the worst pain imaginable.
___________________________________________________________________________________________________________________________
MEET ARIELLE*
How does this compare with your HS patients?
* Fictitious patient. May not be representative of all patients.
BMI=body mass index; NRS=numeric rating scale
• 22-year-old university student
• 81 kg
• BMI: 30.5 kg/m2
• Duration of disease: 4 years
• Lesion location/count:
-Axilla: 2 abscesses in left axilla
-Buttocks: 1 nodule, right buttock
• Daily skin pain: NRS score=3/10
• Despite treatment with topical therapy and antibiotics,
experiences at least 4 flares a year
___________________________________________________________________________________________________________________________
MEET NATHALIA*
How does this compare with your HS patients?
* Fictitious patient. May not be representative of all patients.
BMI=body mass index; NRS=numeric rating scale
• 30-year-old dentist
• 80 kg
• BMI: 30 kg/m2
• Duration of disease: 10 years
• Lesion location/count:
- Axilla: 2 abscesses, 3 nodules involving both axillae
- Under breasts: 2 nodules, 1 fistula under left breast
• Daily skin pain: NRS score=5/10
• Currently treated with antibiotics; however, continues
to experience pain and monthly flares
___________________________________________________________________________________________________________________________
MEET BRIANA*
How does this compare with your HS patients?
* Fictitious patient. May not be representative of all patients.
BMI=body mass index; NRS=numeric rating scale
• 21-year-old secretary
• 80 kg
• BMI: 29 kg/m2
• Duration of disease: 3 years
• Lesion location/count:
- Axilla: 1 abscess, in right axilla
- Under breasts: 1 abscess under right breast.
3 nodules under left breast
- Groin: 3 nodules, 1 fistula of left groin
• Daily skin pain: NRS score=6/10
• Despite conventional treatment, continues to develop
lesions and experiences monthly flares
___________________________________________________________________________________________________________________________
MEET ALEXIS*
How does this compare with your HS patients?
* Fictitious patient. May not be representative of all patients.
BMI=body mass index; NRS=numeric rating scale
• 25-year-old elementary school teacher
• 85 kg
• BMI: 28 kg/m2
• Duration of disease: 6 years
• Lesion location/count:
- Axilla: 2 abscesses, 4 nodules in right axilla
- Under breasts: 5 nodules total involving both breasts
- Groin: 3 nodules, 2 fistulas of left groin
- Peri-anal: 1 fistula
• Daily skin pain: NRS score=7/10
• Has not responded to the conventional treatments
prescribed by her doctor and experiences weekly flares
___________________________________________________________________________________________________________________________
MEET DAVID*
How does this compare with your HS patients?
* Fictitious patient. May not be representative of all patients.
BMI=body mass index; NRS=numeric rating scale
• 46-year-old janitor
• 95 kg
• BMI: 38 kg/m2
• Duration of disease: 26 years
• Lesion location/count:
- Axilla: Left axilla: 2 abscesses, 6 nodules, 4 fistulas;
right axilla: 4 nodules, 1 fistula
- Groin: Left groin: 2 abscesses, 4 fistulas; right groin:
8 nodules, 3 fistulas
- Buttocks: 1 abscess, 10 nodules
- Peri-anal: 2 nodules, 5 fistulas
• Daily skin pain: NRS score=9/10
• Experiences weekly flares despite conventional
treatment
Safety information
Click here for additional information and for a link to the Product Monograph discussing:
• Contraindications in patients with severe infections such as sepsis, tuberculosis (TB) and opportunistic infections, and moderate to severe heart failure (NYHA class III/IV).
• The most serious warnings and precautions regarding hepatosplenic T-cell lymphoma, serious infections and pediatric malignancy.
• Other relevant warnings and precautions regarding concurrent administration with other biologic disease-modifying antirheumatic drugs (DMARDs) or other tumour necrosis factor (TNF) antagonists not recommended, switching between biological DMARDs, surgery, patients with congestive heart failure, hematologic events, hypersensitivity reactions, autoimmunity, immunosuppression, immunizations, infections including TB, opportunistic infections and hepatitis B virus reactivation, malignancies including malignancies in pediatric patients and young adults, lymphoma and non-lymphoma malignancy, neurologic events, uveitis and central demyelinating disorders, pregnant or nursing women, and geriatrics.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
The Product Monograph is also available by calling us at 1-866-8HUMIRA (1-866-848-6472).
References:
1. HUMIRA Product Monograph. AbbVie Corporation.
2. Kimball AB, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016;375:422-34.